YNYosuke Nishio

Yosuke Nishio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yosuke Nishio has a total of 214 co-authors. Here are the top co-authors by number of shared publications:

  • Tomoo Ogi

    Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan

    10 shared publications
  • Shinji Saitoh

    Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan

    7 shared publications
  • Kohji Kato

    School of Biochemistry, Faculty of Life Sciences, University of Bristol, Bristol BS8 1TD, UK

    3 shared publications
  • Yoshihiko Kawano

    Department of Pediatrics, Toyota Memorial Hospital, Toyota, Japan

    3 shared publications
  • Hironobu Morinaga

    Department of Genetics, Research Institute of Environmental Medicine (RIeM), Nagoya University, Nagoya, Japan

    2 shared publications
  • Hisashi Oishi

    Department of Comparative and Experimental Medicine, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, 467-8602, Japan

    2 shared publications

Latest Publications

  • Open Access

    Cerebrospinal fluid α-synuclein seed amplification assay positivity identifies a prognostically distinct subgroup in amyotrophic lateral sclerosis

    by Kazuki Obara, Andrea Mastrangelo, Agustina Ranieri, Shorena Janelidze, Daisuke Ito, Munetaka Yamamoto, Veria Vacchiano, Rocco Liguori, Serena Caldera, Yuichi Riku, et al.

    Background: α-synuclein (Lewy body-type) co-pathology has been identified at autopsy in a subset of patients with amyotrophic lateral sclerosis (ALS). However, its prevalence and prognostic relevance in vivo remain poorly characterized. Methods: We analyzed baseline cerebrospinal fluid (CSF) α-synuclein seed amplification assay (αSyn SAA) status in 443 patients with ALS from two cohorts (Nagoya, Japan, n = 248; Bologna, Italy, n = 195). Samples were classified as strong-positive, weak-positive, or negative based on RT-QuIC reactivity across replicate wells, using the assay’s established a priori criteria at initial and repeat testing; classifications were corroborated by quantitative kinetic parameters. We compared age– and sex-adjusted odds of positivity in ALS with those in cognitively unimpaired (CU; n = 999; stratified by amyloid-β [Aβ] status), Aβ-positive mild cognitive impairment ( n = 224), and Alzheimer’s disease dementia ( n = 319) groups from the Swedish BioFINDER cohort. In ALS, we examined tracheostomy-free survival and longitudinal functional decline using cohort-stratified Cox and linear mixed-effects models, respectively. We also assessed interactions between αSyn SAA status and baseline CSF neurofilament light chain (NfL). Prognostic analyses were performed in sporadic ALS and repeated after including familial or genetic cases. Results: Strong αSyn SAA positivity was detected in 24/443 patients with ALS (5.4%); overall positivity, including weak-positive samples, was 37/443 (8.4%). Patients with ALS did not have significantly higher odds of SAA positivity than Aβ-negative CU participants (age– and sex-adjusted odds ratio [OR] 1.33, 95% CI [0.82, 2.14]) and had significantly lower odds than patients with Alzheimer’s disease dementia (OR 0.44, [0.27, 0.70]). Among patients with sporadic ALS, strong αSyn SAA positivity was associated with shorter tracheostomy-free survival after adjustment for established predictors including NfL (adjusted HR 2.08 [1.25, 3.45]), whereas weak positivity showed no clear survival association. In linear mixed-effects models, strong αSyn SAA positivity modified the association between NfL and ALSFRS-R decline (NfL × αSyn SAA × time interaction β−0.70 points/month [−1.26, −0.14] per SD NfL). These findings persisted in analyses including familial or genetic ALS cases and in those restricted to Aβ-negative patients. Neuropathological findings ( n = 5) were concordant with the CSF αSyn SAA classification. Conclusions: A strong α-synuclein seeding profile was uncommon in ALS but identified a subgroup with shorter survival and a stronger association between NfL and functional decline. These findings provide ante-mortem evidence that α-synuclein co-pathology may contribute to prognostic heterogeneity in ALS.

  • Open Access

    Resolving complex splicing outcomes in ALDH3A2 using long-read transcriptome sequencing

    by Atsuna Kamei, Yosuke Nishio, Yukako Muramatsu, Kotaro Tsukada, Yasuyoshi Oka, Koyo Tsujikawa, Hironobu Morinaga, Hirokazu Kurahashi, Hideki Muramatsu, Takuya Takeichi, et al.

    Long-read transcriptome sequencing (Iso-Seq) resolves complex aberrant splicing that is difficult to characterize by short-read RNA sequencing. ALDH3A2 encodes fatty aldehyde dehydrogenase, and biallelic pathogenic variants cause Sjögren–Larsson syndrome (SLS), a rare autosomal recessive neurocutaneous disorder. Here, we describe two siblings with typical SLS features (developmental delay, hypotonia, and ichthyosis) together with laryngeal cartilage calcification and recurrent airway obstruction, a previously unreported manifestation. Exome sequencing identified compound heterozygous ALDH3A2 variants: a canonical splice-site variant and a synonymous variant of uncertain DNA-level pathogenicity. Iso-Seq quantified three aberrant isoforms with distinct fates: the exon 5–skipped transcript was a primary target of nonsense-mediated mRNA decay (NMD); the exon 2–skipped transcript carried a premature termination codon but escaped NMD; and the in-frame exon 4–5–skipped transcript escaped NMD and was the only aberrant isoform predicted to yield a translated in-frame protein, despite an internal 109-amino-acid deletion spanning both NAD-binding and catalytic domains. Structural modeling predicted reduced stability and enzymatic function, and ALDH3A2 protein was virtually undetectable in patient cells, supporting pathogenicity. Long-read transcript analysis thus quantitatively prioritizes the dominant protein-producing isoform for functional interrogation, and expands the clinical spectrum of SLS to include laryngeal cartilage calcification.

  • Open Access

    Biallelic VPS41 Variants in Autosomal Recessive Spinocerebellar Ataxia 29 Resolved by Long‐Read Sequencing and RNA Analysis

    by Natsuki Nakamura, Yosuke Nishio, Hiromi Nyuzuki, Ai Fukushima, Masaki Miura, Yu Kobayashi, Risako Ishioka, Kotaro Tsukada, Yasuyoshi Oka, Koyo Tsujikawa, et al.

    Background: Biallelic variants in VPS41 , encoding a subunit of the HOPS complex, cause autosomal recessive spinocerebellar ataxia 29 (SCAR29), a rare neurodevelopmental disorder with an incompletely defined phenotypic and molecular spectrum. Methods: We investigated a 24‐year‐old man with cerebellar ataxia, hypotonia, and intellectual disability. Exome sequencing identified four candidate VPS41 variants. Because maternal DNA was unavailable, long‐read genome sequencing was performed to determine allelic configuration, followed by RNA and protein analyses. Results: In addition to typical SCAR29 features, the patient showed previously unreported findings, including swan‐neck deformities and pes cavus. Long‐read genome sequencing demonstrated that two VPS41 variants were in trans. RNA analysis revealed distinct splicing consequences: one allele produced an out‐of‐frame transcript predicted to undergo nonsense‐mediated decay, whereas the other generated an in‐frame exon‐skipped transcript. These complementary defects reduced VPS41 expression at both transcript and protein levels, supporting pathogenicity and variant reclassification. Conclusion: Our findings expand the phenotypic spectrum of VPS41 ‐related disease and highlight the value of long‐read allelic resolution in clarifying pathogenic mechanisms in rare genetic disorders.

  • Open Access

    Long-read RNA sequencing reveals extensive transcript isoform changes in a patient with IFAP syndrome with a recurrent intronic MBTPS2 variant

    by Toshihiko Iwaki, Yosuke Nishio, Sachiyo Takagi, Keiichiro Fujii, Masanori Fujimoto, Emi Sato, Yuji Nakamura, Daisuke Ieda, Yutaka Negishi, Ayako Hattori, et al.

    Hemizygous pathogenic variants in MBTPS2 located at Xp22.12 cause IFAP syndrome, which is characterized by the triad of ichthyosis, alopecia and photophobia. Here we identified a hemizygous intronic variant in MBTPS2 (NM_015884: c.970+5G>A) in a patient with alopecia, follicular keratinization, developmental delay and epilepsy which were compatible with IFAP syndrome. The variant has been reported to cause skipping of 20 bases in exon 7, leading to the premature termination codon. To further investigate the consequence of the variant, we performed long-read RNA sequencing using RNA extracted from fibroblasts cultured from the patient’s skin. Long-read RNA sequencing revealed skipping of exons 6 and 7, in addition to the previously reported 20-base skipping in exon 7. Furthermore, the expression of normal transcripts, as observed in healthy skin, was markedly reduced. Long-read RNA sequencing is a powerful tool for simultaneously identifying diverse transcript isoforms, making it highly valuable for elucidating the effects of splice-altering variants.

  • Open Access

    Pathogenic variants in the cohesin loader subunit MAU2 underlie a distinct Cornelia de Lange Syndrome subtype

    by Ilaria Parenti, Alina Hesters, Marta Gil-Salvador, Laura Duffy, Deniz Kanber, Jasmin Beygo, Jennifer Kerkhof, Laura Steenpaß, Elsa Leitão, Julia Woestefeld, et al.

    The role of the cohesin complex depends on the cohesin loader proteins NIPBL and MAU2. While NIPBL variants are a major cause of Cornelia de Lange Syndrome (CdLS), the role of MAU2 in disease is unclear. We describe 18 individuals carrying 15 heterozygous MAU2 variants and demonstrate pathogenicity through functional analyses. In-frame MAU2 variants predominantly impair NIPBL–MAU2 interaction, whereas truncating variants cause MAU2 haploinsufficiency and lead to NIPBL reduction. Most individuals exhibit a DNA methylation profile compatible with the CdLS episignature. We also describe two MAU2 -specific episignatures that reflect variant-dependent molecular consequences. Affected individuals display a wide range of phenotypes, from classic CdLS to milder presentations, with short stature and microcephaly as major features. A heterozygous Mau2 knockout mouse model recapitulates these traits, confirming the causal role of MAU2 disruption in vivo. Our study establishes MAU2 as a CdLS-associated gene and delineates a MAU2 -related chromatinopathy with variable expressivity.


  • Open Access

    Compound heterozygosity of EXOSC2 ‘missense’ variants causes a bi-allelic decrease in protein expression through novel unexpected pathomechanisms

    by Shin Hayashi, Kenichiro Yamada, Takuma Mori, Yasuyo Suzuki, Yosuke Nishio, Tomoo Ogi, Mie Inaba

    EXOSC2 encodes one of the 11 components of the RNA exosome complex degrading various types of RNA. Pathogenic variants of some EXOSC genes cause genetic disorders with similar phenotypes, including intellectual disability (ID), microcephaly, and pontocerebellar hypoplasia. However, little is known regarding EXOSC2 . We report detailed analyses of compound heterozygosity of novel EXOSC2 variants, comprising paternally-inherited c.14T > G (p.M5R) and maternally-inherited c.317C > T (p.S106L), identified in a patient with ID, epilepsy, and microcephaly. Although the two variants appeared ‘missense,’ they respectively decreased protein EXOSC2 expression through novel pathomechanisms. c.14T > G may have decreased EXOSC2 expression by impaired efficiency during translational initiation. Interestingly, other synonymous codons didn’t decrease the expression, suggesting the decreased expression depended on the nucleotide change instead of residue change. The second variant, c.317C > T, caused unexpected exon 4 skipping, leading to decreased EXOSC2 expression, although the nucleotide 317C was in the middle of exon 4. Since the exon skipping didn’t occur due to other changes in nucleotides adjacent to c.317C, only c.317C > T critically reduced the function of the exon enhancer element. Altogether, we identified two novel pathomechanisms explaining the decrease in EXOSC2 expression. These findings suggest the possibility that we may overlook such kind of variants decreasing gene expression, which could cause disorders. Additionally, the etiology of the current case is a decline of one of the 11 components of the exosome, similar to previously-reported disorders by other genes in the EXOSC family, with overlapping clinical features. Thus, these disorders may be integrated into a new disease concept termed “ RNA exosomepathy .”

  • Gerstmann–Sträussler–Scheinker disease mimicking primary progressive multiple sclerosis: A case with positive oligoclonal bands

    by Miwa Ito, Hiroki Masuda, Marie Morooka, Atsuhiko Sugiyama, Hajime Yokota, Tomoo Ogi, Yosuke Nishio, Satoshi Kuwabara

    Background: Certain prion diseases have been observed to exhibit positive oligoclonal bands (OCBs), a key marker in diagnosing multiple sclerosis (MS). Methods: We describe a case of Gerstmann–Sträussler–Scheinker (GSS) disease presenting with positive OCBs, no sustained abnormalities in the cortex or basal ganglia, and limited brain atrophy progression, mimicking the clinical profile of primary progressive MS (PPMS). Conclusion: Atypical white matter findings and warning signs should prompt caution in diagnosing MS. GSS should be recognized as a potential differential diagnosis for PPMS.

  • Open Access

    TFIIH-p52ΔC defines a ninth xeroderma pigmentosum complementation–group XP-J and restores TFIIH stability to p8-defective trichothiodystrophy

    by Yuka Nakazawa, Lin Ye, Yasuyoshi Oka, Hironobu Morinaga, Kana Kato, Mayuko Shimada, Kotaro Tsukada, Koyo Tsujikawa, Yosuke Nishio, Hiva Fassihi, et al.

    Few drugs are available for rare diseases due to economic disincentives. However, tailored medications for extremely rare disorders (N-of-1) offer a ray of hope. Artificial antisense oligonucleotides (ASOs) are now best known for their use in spinal muscular atrophy (SMA). The success of nusinersen/Spinraza for SMA indicates the potential of ASO therapies for other rare conditions. We propose a strategy to develop N-of-1 ASOs for treating one form of trichothiodystrophy (TTD), a rare condition with multisystem abnormalities and reduced life expectancy, associated with instability and greatly reduced amounts of the DNA-repair/transcription factor TFIIH. The therapeutic targets carry mutations in GTF2H5 , encoding the TFIIH-p8 subunit. This approach was inspired by the diagnosis and molecular dissection of a xeroderma pigmentosum (XP) case with mutations in GTF2H4 , encoding the TFIIH-p52 subunit. This is newly classified as a ninth XP complementation–group, XP-J, identified 5 decades after the discovery of the other XP complementation–groups. The p8-p52 interaction is required to support the TFIIH-complex formation, and the patient’s p52 C-terminal truncation results in the complete absence of p8 in TFIIH. However, intriguingly, TFIIH remained stable in vivo, and the patient with XP-J did not exhibit any TTD-features. The aim of our ASO-design is to induce a C-terminal truncation of p52 and we have successfully stabilized TFIIH in p8-deficient cells from patients with TTD-A.


  • Ritscher-Schinzel syndrome can be characterized as an endosomal recyclinopathy

    by Kohji Kato, Yosuke Nishio, Kirsty J. McMillan, Aljazi Al-Maraghi, Hester Y. Kroes, Mohamed S. Abdel-Hamid, Emma Jones, Shrestha Shaw, Aya Yoshida, Shiomi Otsuji, et al.

    Ritscher-Schinzel syndrome (RSS) is a congenital malformation syndrome characterized by cerebellar, cardiac, and craniofacial malformations and phenotypes associated with liver, skeletal, and kidney dysfunction. The genetic cause of RSS remains to be fully defined, and limited information is available regarding the root cause of the multiple tissue phenotypes. Causative mutations in the Commander multiprotein assembly are an emerging feature of this syndrome. Commander organizes the sorting nexin-17 (SNX17)–dependent recycling of hundreds of integral membrane proteins through the endosomal network. Here, we identify previously unrecognized cohorts of patients with RSS that we genetically and clinically analyzed to identify causative genes in the copper metabolic murr1 domain–containing (COMMD) proteins COMMD4, COMMD9, and coiled-coil domain containing 93 (CCDC93) subunits of the Commander complex. Using interactome analysis, we determined that these mutations disrupted Commander assembly and, through cell surface proteomics, that this reduces tissue-specific presentation of cell surface integral membrane proteins essential for kidney, bone, and brain development. We established that these integral proteins contained ΦxNPxY/F or ΦxNxxY/F sorting motifs in their cytoplasmic-facing domains (where Φ is a hydrophobic residue and x is any residue) that are recognized by SNX17 to drive their Commander-dependent endosomal recycling. Last, through generation of mouse models of RSS, we show replication of RSS-associated clinical phenotypes including proteinuria, skeletal malformation, and neurological impairment. Our data establish RSS as a “recyclinopathy” that arises from a dysfunction in the Commander endosomal recycling pathway.


  • Open Access

    De novo CDKN1C variant in Beckwith–Wiedermann spectrum with atypical complications

    by Yuri Moriura, Yosuke Nishio, Shintaro Ichimura, Haruka Noda, Yoshihiro Tanahashi, Hikaru Yamamoto, Yuka Nakazawa, Taichi Oso, Yoshiaki Sato, Toshiki Takenouchi, et al.

    Beckwith–Wiedemann spectrum (BWSp) is a genomic imprinting disorder characterized by a wide range of clinical features. Here we report an infant with BWSp and atypical features, for whom long-read sequencing confirmed a de novo CDKN1C variant that occurred on the maternally inherited allele and excluded other genetic etiologies. These findings not only expand the BWSp concept but also highlight the potential value of allelic origin analysis in cases with atypical presentations.